Confirmed Psoriatic Arthritis
Diagnosis per CASPAR criteria
All Pathways
RheumatologyManagement
Psoriatic Arthritis Management (EULAR 2023)
Psoriatic Arthritis Management (EULAR 2023): Confirmed Psoriatic Arthritis → Overarching Principles → Domain Assessment → Mild Disease? → NSAIDs (Short-...
Pathway Overview
15 steps
Algorithm Steps
15 total
01Start 02Action Overarching Principles
Key principles for PsA management
- Treatment goal: remission or low disease activity (MDA, DAPSA)
- Shared decision-making with patient
- Address ALL domains: peripheral, axial, skin, enthesitis, dactylitis
- Consider comorbidities: CV disease, metabolic syndrome, uveitis, IBD
- Multi-disciplinary care (rheum, derm, ophthalmology)
03Action Domain Assessment
Identify predominant manifestations
- Peripheral arthritis: joint count, swelling
- Axial involvement: inflammatory back pain, limited mobility
- Skin/nails: PASI score, BSA, nail dystrophy
- Enthesitis: LEI, MASES scores
- Dactylitis: digit count
04Decision Mild Disease?
Few joints, mild skin, no poor prognostic factors
- Poor prognostic factors: polyarticular, structural damage, elevated CRP/ESR, dactylitis
- Mild: oligoarticular, no erosions, mild skin involvement
05Action NSAIDs (Short-Term Only)
For mild PsA
- NSAIDs monotherapy ONLY for mild disease and short-term
- NOT long-term monotherapy
- If poor prognostic factors: start csDMARD rapidly
- Oral GC NOT recommended (may flare psoriasis)
06Decision Target Achieved at 3-6 Months?
Assess all domains
- MDA (Minimal Disease Activity): 5/7 criteria
- DAPSA remission (≤4) or low activity (≤14)
- If one domain uncontrolled: escalate based on that domain
07Action Maintenance Therapy
Sustained remission or MDA
- Continue effective therapy
- May consider cautious dose reduction in sustained MDA
- Do NOT stop bDMARD (relapse risk)
- Continue csDMARD if using combination
- Monitor all domains regularly
08Outcome PsA Controlled
MDA or remission achieved across all domains
09Action bDMARD Therapy
After csDMARD failure
- TNF inhibitor (adalimumab, etanercept, infliximab, certolizumab, golimumab)
- IL-17 inhibitor (secukinumab, ixekizumab, bimekizumab)
- IL-23 inhibitor (guselkumab, risankizumab) - especially if skin predominant
- Ustekinumab (IL-12/23) - less preferred unless skin-predominant
- Consider skin severity in selection (IL-17i, IL-23i excellent for psoriasis)
10Warning ⚠️ Domain-Specific Drug Selection
Comorbidities influence choice
- Axial PsA: TNFi or IL-17i (like axSpA); NOT IL-23i (limited axial data)
- IBD: TNFi (adalimumab, infliximab); AVOID IL-17i (may worsen IBD)
- Uveitis: TNFi monoclonals preferred
- Severe skin: IL-17i, IL-23i excellent; TNFi less effective for skin
11Decision bDMARD Response at 3-6 Months?
Assess all domains
- Path rejoins step 07Shared downstream outcome
12Action Switch bDMARD or JAK Inhibitor
After bDMARD failure
- Switch to different mechanism bDMARD
- JAK inhibitors: tofacitinib, upadacitinib
- EULAR suggests JAKi AFTER bDMARD failure (safety data ongoing)
- Assess CV/VTE risk before JAKi (similar to RA)
- Path rejoins step 08Shared downstream outcome
13Warning Specialist Referral
Refractory disease, complex comorbidities, clinical trial
14Action csDMARD Therapy (Peripheral PsA)
First-line for peripheral arthritis
- Methotrexate PREFERRED (15-25 mg/week with folic acid)
- Alternative: Leflunomide, Sulfasalazine (less evidence)
- Initiate rapidly if poor prognostic factors
- csDMARDs NOT effective for axial disease
- Short-term local GC injections acceptable
15Warning ⚠️ Glucocorticoid Caution
Not recommended in PsA
- Oral GC NOT recommended (may cause psoriasis flare on withdrawal)
- If absolutely needed: low dose, short duration
- Local injections (IA, peritendinous) acceptable
- Enthesitis: steroid injection controversial
- Path rejoins step 06Shared downstream outcome
Guideline Source
EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2023 Update
Clinical Safety Information
Clinical Decision Support — Not a Substitute for Clinical Judgment
Individual patient factors may require deviation from these recommendations.
Known Limitations
- Skin severity assessment requires dermatology input for severe psoriasis
- IBD and uveitis impact drug selection (see notes)
- Pediatric PsA not addressed
- Drug availability varies by region
- Cardiovascular risk assessment not detailed
Contraindicated Populations
pediatric
Applicable Regions
EUUSAU
AU: ARA endorses EULAR/GRAPPA recommendations
EU: EULAR 2023 is primary guidance
US: ACR/NPF 2018 also available; GRAPPA recommendations referenced
Version 1Next review: 2028-01-01
Next steps
Finish the workflow by opening the most relevant calculator, then convert the session into a live account when you are ready.
Related Resources
Frequently Asked Questions
What is the Psoriatic Arthritis Management (EULAR 2023)?
The Psoriatic Arthritis Management (EULAR 2023) is a management clinical algorithm for Rheumatology. It provides a structured decision tree to guide clinical decision-making, based on EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2023 Update.
What guideline is the Psoriatic Arthritis Management (EULAR 2023) based on?
This algorithm is based on EULAR Recommendations for the Management of Psoriatic Arthritis with Pharmacological Therapies: 2023 Update (DOI: 10.1136/ard-2024-225531).
What are the limitations of the Psoriatic Arthritis Management (EULAR 2023)?
Known limitations include: Skin severity assessment requires dermatology input for severe psoriasis; IBD and uveitis impact drug selection (see notes); Pediatric PsA not addressed; Drug availability varies by region; Cardiovascular risk assessment not detailed. Individual patient factors may require deviation from these recommendations.
Get AI-Powered Analysis Alongside This Algorithm
In AttendMe.ai, the Psoriatic Arthritis Management (EULAR 2023) appears automatically when your clinical question matches — alongside evidence from 3M+ peer-reviewed articles.
Try AttendMe Free